Skip to content

Acute Ischemic Stroke Reperfusion Therapy - Recombinant Human TNK Tissue-type Plasminogen Activator for Injection (rhTNK-tPA, Mingfule) Real-World Data Monitoring Registry Study for Intravenous Thrombolysis

Acute Ischemic Stroke Reperfusion Therapy - Recombinant Human TNK Tissue-type Plasminogen Activator for Injection (rhTNK-tPA, Mingfule) Real-World Data Monitoring Registry Study for Intravenous Thrombolysis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126479
Enrollment
Unknown
Registered
2026-06-09
Start date
2026-06-10
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

Case series:None

Sponsors

Linyi People's Hospital (Shandong Provincial Clinical Research Center for Geriatric Diseases)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age 18 years or older adult patients; 2. Meet the diagnostic criteria for acute ischemic stroke and confirmed by imaging examination (head CT or MRI); 3. Receive rhTNK-tPA intravenous thrombolytic therapy in this institution; 4. Informed consent obtained and written consent signed by the patient or legal guardian; 5. Able to cooperate for follow-up.

Exclusion criteria

Exclusion criteria: 1. Patients who have already received reperfusion therapy outside the hospital (such as patients who have received intravenous thrombolysis before admission); 2. Patients participating in other clinical trials that may affect the results of this study.

Design outcomes

Primary

MeasureTime frame
Symptomatic intracranial hemorrhage within 36 hours after intravenous thrombolysis (according to the ECASS III definition);Good functional prognosis at 90 days (mRS score =1);

Secondary

MeasureTime frame
Functional independence at 90 days (mRS score =2);90-day ordinal mRS score;Change in 24h NIHSS relative to baseline (short-term functional prognosis);Change in 7-day/discharge NIHSS relative to baseline (short-term functional prognosis);All-cause mortality and time of death within 90 days;Stroke recurrence and recurrence time within 90 days;Serious adverse events during hospitalization;

Countries

China

Contacts

Public ContactZiRan Wang

Linyi People's Hospital

wzr0806@163.com+86 139 5499 3801

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026